Compare NYAX & SLNO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NYAX | SLNO |
|---|---|---|
| Founded | 2005 | 1999 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.3B | 2.3B |
| IPO Year | 2022 | 2014 |
| Metric | NYAX | SLNO |
|---|---|---|
| Price | $66.80 | $53.01 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 4 | 9 |
| Target Price | $49.50 | ★ $83.00 |
| AVG Volume (30 Days) | 47.0K | ★ 1.5M |
| Earning Date | 05-12-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 108.90 |
| EPS | N/A | ★ 0.59 |
| Revenue | N/A | ★ $1,450,788.00 |
| Revenue This Year | $30.66 | $150.46 |
| Revenue Next Year | $21.70 | $50.37 |
| P/E Ratio | ★ $89.78 | $89.83 |
| Revenue Growth | N/A | ★ 138.82 |
| 52 Week Low | $38.50 | $29.43 |
| 52 Week High | $75.00 | $89.12 |
| Indicator | NYAX | SLNO |
|---|---|---|
| Relative Strength Index (RSI) | 51.00 | 77.32 |
| Support Level | $51.53 | $48.91 |
| Resistance Level | $74.83 | $55.47 |
| Average True Range (ATR) | 2.52 | 0.05 |
| MACD | -0.96 | -0.52 |
| Stochastic Oscillator | 31.58 | 100.00 |
Nayax Ltd is an end-to-end retail technology platform for unattended commerce. It unifies payments, operations management, and customer engagement tools into a powerful, adaptable platform for modern commerce. It provides solutions that empower businesses to enhance customer experience, accept cashless payments, and manage their operations with a robust Internet of Things (IoT) software platform, helping achieve long-term growth. The company addresses a broad range of retail verticals, including all types of vending machines, coffee machines, unattended checkout counters, self-service kiosks, ticketing machines, car wash stations, gaming machines, amusement rides, laundromats, EV charging stations, and many more.
Soleno Therapeutics Inc is a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases. Its product candidate DCCR (Diazoxide Choline) Extended-Release tablets, is a proprietary extended-release formulation of a crystalline salt of diazoxide. DCCR has demonstrated the ability to activate the KATP channel in the brain, pancreas, and fat tissue.